Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 2926 AL 2940

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study

Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen A.

BMJ. 2017 Apr 24;357:j1648. doi: 10.1136/bmj.j1648.

Gene networks in neurodegenerative disorders

Recabarren D, Alarcón M.

Life Sci. 2017 Aug 15;183:83-97. doi: 10.1016/j.lfs.2017.06.009. Epub 2017 Jun 13.

Ceramide and Its Related Neurochemical Networks as Targets for Some Brain Disorder Therapies

Brodowicz J, Przegaliński E, Müller CP, Filip M.

Neurotox Res. 2018 Feb;33(2):474-484. doi: 10.1007/s12640-017-9798-6. Epub 2017 Aug 25.

Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinson's and Alzheimer's Diseases

Boyko AA, Troyanova NI, Kovalenko EI, Sapozhnikov AM.

Int J Mol Sci. 2017 Dec 6;18(12):2633. doi: 10.3390/ijms18122633.

Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome

Zis P, Strydom A.

Free Radic Biol Med. 2018 Jan;114:3-9. doi: 10.1016/j.freeradbiomed.2017.08.024. Epub 2017 Sep 1.

Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review

Bansal R, Singh R.

Med Res Rev. 2018 Jul;38(4):1126-1158. doi: 10.1002/med.21458. Epub 2017 Jul 11.

Point-of-Care Devices Using Disease Biomarkers To Diagnose Neurodegenerative Disorders

Wei TY, Fu Y, Chang KH, Lin KJ, Lu YJ, Cheng CM.

Trends Biotechnol. 2018 Mar;36(3):290-303. doi: 10.1016/j.tibtech.2017.11.004. Epub 2017 Dec 11.

miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease

Mushtaq G, Greig NH, Anwar F, Zamzami MA, Choudhry H, Shaik MM, Tamargo IA, Kamal MA.

Med Chem. 2016;12(3):217-25. doi: 10.2174/1573406411666151030112140.

Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins

Butterfield DA, Palmieri EM, Castegna A.

Expert Rev Proteomics. 2016;13(3):259-74. doi: 10.1586/14789450.2016.1149470.

Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice

Blennow K, Biscetti L, Eusebi P, Parnetti L.

Mov Disord. 2016 Jun;31(6):836-47. doi: 10.1002/mds.26656. Epub 2016 May 4.

Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson's and Alzheimer's Disease Patients

Montarolo F, Perga S, Martire S, Navone DN, Marchet A, Leotta D, Bertolotto A.

Neurotox Res. 2016 Oct;30(3):338-44. doi: 10.1007/s12640-016-9626-4. Epub 2016 May 9.

Cognitive interventions in Alzheimer's and Parkinson's diseases: emerging mechanisms and role of imaging

Vemuri P, Fields J, Peter J, Klöppel S.

Curr Opin Neurol. 2016 Aug;29(4):405-11. doi: 10.1097/WCO.0000000000000346.

Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia

Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, Kramberger MG, Zetterberg H, Mollenhauer B, Boada M, Aarsland D; European DLB Consortium.

Mov Disord. 2016 Aug;31(8):1203-8. doi: 10.1002/mds.26668. Epub 2016 Jun 14.

Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases

Parnetti L, Eusebi P, Lleó A.

Front Neurol Neurosci. 2016;39:117-23. doi: 10.1159/000445452. Epub 2016 Jul 26.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias